CRISPR/Cas-Mediated genome editing of Staphylococcus aureus for studying Phage-Pathogenicity Island-Host Interactions
Location
Sydnor Performance Hall, Schewel Hall
Access Type
Open Access
Presentation Type
Oral presentation
Entry Number
81
Start Date
4-16-2026 1:30 PM
End Date
4-16-2026 1:45 PM
School
School of Medicine and Health Sciences
Department
Biology
Keywords
Staph aureus, antibiotic resistance, CRISPR-Cas, Bacteria, Gene Editing
Abstract
Staphylococcus aureus is a gram-positive cocci that is a common member of our microbiota, living frequently on our skin and in our nasal passages. It is known for its wide variety of clinical manifestations, including endocarditis, scalded skin syndrome, toxic shock syndrome, food poisoning, sepsis, folliculitis, impetigo, and many other infections. It is widely recognized for being acquired in both hospital and community settings and is often resistant to multiple drugs. This poses a major problem, both in the United States and globally, as many treatments are no longer effective. MRSA, or Methicillin-Resistant Staphylococcus, is one example of the many drug-resistant strains that healthcare workers deal with daily. When S. aureus is living in its natural environment, namely on the skin and in the nasal passages, it does not cause infection, but if it enters the bloodstream or internal body cavities, serious infections can arise. One of the main reasons we are studying S. aureus is to develop effective strategies for combating its virulence and addressing the growing challenges of antibiotic resistance in healthcare.
The goal of this project is to develop mutant strains of Staphylococcus aureus for the purposes of teaching and investigating bacteriophages, pathogenicity islands, and broader interactions between these elements and the host bacterium. The Quanjiang Lab (2017) successfully used their pCasSA system to create and test multiple mutant strains of S. aureus by utilizing the CRISPR/Cas system, a bacterial defense mechanism that allows precise targeting and cutting of specific DNA sequences. This SOP allows for direct genome editing with the option of introducing deletions, insertions, and single-base substitutions. Our objective is to modify and adapt the protocol used in the original study for use in our lab, and validate our modifications by constructing agrA gene mutants, knocking out AgrA protein, a transcriptional regulator that affects many virulence phenotypes, one of which is hemolysis. First, we will obtain the pCasA plasmid from AddGene. Next, we will design custom primers (oligonucleotides) to generate the required guide RNA and modify the plasmid to produce the desired mutant. The NEBuilder® HiFi DNA Assembly Master Mix will be used to assemble the modified plasmid constructs via Gibson assembly. Finally, the constructed plasmid will be electroporated into S. aureus, and transformed bacteria will be grown on 5% Blood Agar plates to permit visual screening to identify target mutants by loss of hemolysis.
Primary Faculty Mentor(s)
Dr. Jamie Brooks
Primary Faculty Mentor(s) Department
Biology Department
Additional Faculty Mentor(s)
Dr. Rachel Willis and Dr. Price Blair
Rights Statement
The right to download or print any portion of this material is granted by the copyright owner only for personal or educational use. The author/creator retains all proprietary rights, including copyright ownership. Any editing, other reproduction or other use of this material by any means requires the express written permission of the copyright owner. Except as provided above, or for any other use that is allowed by fair use (Title 17, §107 U.S.C.), you may not reproduce, republish, post, transmit or distribute any material from this web site in any physical or digital form without the permission of the copyright owner of the material.
CRISPR/Cas-Mediated genome editing of Staphylococcus aureus for studying Phage-Pathogenicity Island-Host Interactions
Sydnor Performance Hall, Schewel Hall
Staphylococcus aureus is a gram-positive cocci that is a common member of our microbiota, living frequently on our skin and in our nasal passages. It is known for its wide variety of clinical manifestations, including endocarditis, scalded skin syndrome, toxic shock syndrome, food poisoning, sepsis, folliculitis, impetigo, and many other infections. It is widely recognized for being acquired in both hospital and community settings and is often resistant to multiple drugs. This poses a major problem, both in the United States and globally, as many treatments are no longer effective. MRSA, or Methicillin-Resistant Staphylococcus, is one example of the many drug-resistant strains that healthcare workers deal with daily. When S. aureus is living in its natural environment, namely on the skin and in the nasal passages, it does not cause infection, but if it enters the bloodstream or internal body cavities, serious infections can arise. One of the main reasons we are studying S. aureus is to develop effective strategies for combating its virulence and addressing the growing challenges of antibiotic resistance in healthcare.
The goal of this project is to develop mutant strains of Staphylococcus aureus for the purposes of teaching and investigating bacteriophages, pathogenicity islands, and broader interactions between these elements and the host bacterium. The Quanjiang Lab (2017) successfully used their pCasSA system to create and test multiple mutant strains of S. aureus by utilizing the CRISPR/Cas system, a bacterial defense mechanism that allows precise targeting and cutting of specific DNA sequences. This SOP allows for direct genome editing with the option of introducing deletions, insertions, and single-base substitutions. Our objective is to modify and adapt the protocol used in the original study for use in our lab, and validate our modifications by constructing agrA gene mutants, knocking out AgrA protein, a transcriptional regulator that affects many virulence phenotypes, one of which is hemolysis. First, we will obtain the pCasA plasmid from AddGene. Next, we will design custom primers (oligonucleotides) to generate the required guide RNA and modify the plasmid to produce the desired mutant. The NEBuilder® HiFi DNA Assembly Master Mix will be used to assemble the modified plasmid constructs via Gibson assembly. Finally, the constructed plasmid will be electroporated into S. aureus, and transformed bacteria will be grown on 5% Blood Agar plates to permit visual screening to identify target mutants by loss of hemolysis.